TY - JOUR
T1 - Enhancing interventions for prevention of mother-to-child- transmission of hepatitis B virus
AU - Matthews, Philippa C.
AU - Ocama, Ponsiano
AU - Wang, Su
AU - El-Sayed, Manal
AU - Turkova, Anna
AU - Ford, Deborah
AU - Torimiro, Judith
AU - Garcia Ferreira, Ana Cristina
AU - Espinosa Miranda, Angélica
AU - De La Hoz Restrepo, Fernando Pio
AU - Seremba, Emmanuel
AU - Mbu, Robinson
AU - Pan, Calvin Q.
AU - Razavi, Homie
AU - Dusheiko, Geoffrey
AU - Spearman, C. Wendy
AU - Hamid, Saeed
N1 - Funding Information:
PCM is funded by the Wellcome Trust (Grant ref 110110/Z/15/Z), UCLH NIHR Biomedical Research Centre , and receives core funding from the Francis Crick Institute , London. AT and DF receive core funding from the UK Medical Research Council (grants MC_UU_00004/03 ).
Publisher Copyright:
© 2023 The Author(s)
PY - 2023/8
Y1 - 2023/8
N2 - Prevention of mother-to-child transmission of hepatitis B virus (HBV) infection is a cornerstone of efforts to support progress towards elimination of viral hepatitis. Current guidelines recommend maternal screening, antiviral therapy during the third trimester of high-risk pregnancies, universal and timely HBV birth dose vaccination, and post-exposure prophylaxis with hepatitis B immunoglobulin for selected neonates. However, serological and molecular diagnostic testing, treatment and HBV vaccination are not consistently deployed, particularly in many high endemicity settings, and models predict that global targets for reduction in paediatric incidence will not be met by 2030. In this article, we briefly summarise the evidence for current practice and use this as a basis to discuss areas in which prevention of mother-to-child transmission can potentially be enhanced. By reducing health inequities, enhancing pragmatic use of resources, filling data gaps, developing advocacy and education, and seeking consistent investment from multilateral agencies, significant advances can be made to further reduce vertical transmission events, with wide health, societal and economic benefits.
AB - Prevention of mother-to-child transmission of hepatitis B virus (HBV) infection is a cornerstone of efforts to support progress towards elimination of viral hepatitis. Current guidelines recommend maternal screening, antiviral therapy during the third trimester of high-risk pregnancies, universal and timely HBV birth dose vaccination, and post-exposure prophylaxis with hepatitis B immunoglobulin for selected neonates. However, serological and molecular diagnostic testing, treatment and HBV vaccination are not consistently deployed, particularly in many high endemicity settings, and models predict that global targets for reduction in paediatric incidence will not be met by 2030. In this article, we briefly summarise the evidence for current practice and use this as a basis to discuss areas in which prevention of mother-to-child transmission can potentially be enhanced. By reducing health inequities, enhancing pragmatic use of resources, filling data gaps, developing advocacy and education, and seeking consistent investment from multilateral agencies, significant advances can be made to further reduce vertical transmission events, with wide health, societal and economic benefits.
KW - HBIG
KW - HBV
KW - PMTCT
KW - birth dose
KW - elimination
KW - hepatitis B virus
KW - prevention
KW - tenofovir
KW - transmission
KW - vaccination
KW - vertical transmission
UR - http://www.scopus.com/inward/record.url?scp=85164398621&partnerID=8YFLogxK
U2 - 10.1016/j.jhepr.2023.100777
DO - 10.1016/j.jhepr.2023.100777
M3 - Review article
AN - SCOPUS:85164398621
SN - 2589-5559
VL - 5
JO - JHEP Reports
JF - JHEP Reports
IS - 8
M1 - 100777
ER -
